Biomarkers of Cumulative Healthcare Burden in Adults With Multimorbidity

Abstract

Multimorbidity, the co-existence of two or more chronic diseases in a single individual, presents significant challenges to healthcare systems worldwide. The cumulative healthcare burden in adults with multimorbidity leads to increased morbidity, mortality, healthcare utilization, and reduced quality of life. Biomarkers have emerged as valuable tools to quantify and monitor this burden, aiding in risk stratification and personalized intervention. This review synthesizes current evidence on the role of biomarkers in assessing cumulative healthcare burden in individuals with multimorbidity, exploring their clinical utility, mechanistic underpinnings, and implications for patient management. Emphasis is placed on recent advances, practical clinical applications, and future research directions.

Introduction

Multimorbidity is defined as the simultaneous presence of two or more chronic conditions within one individual, and it has become increasingly common due to population aging and the rising prevalence of non-communicable diseases. Managing patients with multimorbidity is complex, requiring holistic assessment of cumulative disease impact, treatment burden, and risk of adverse outcomes. Traditional clinical evaluation often underestimates the dynamic and interactive effects of multiple diseases. Biomarkers provide an objective, quantifiable means to evaluate the cumulative healthcare burden, offering insights into pathophysiological processes, disease progression, and response to interventions. This article reviews the epidemiology, pathophysiology, and clinical relevance of biomarkers in adults with multimorbidity, with a focus on recent evidence and guideline-based recommendations.

Epidemiology / Disease Burden

The global prevalence of multimorbidity among adults ranges from 25% to over 60%, depending on age, socioeconomic status, and healthcare setting. Multimorbidity is associated with increased healthcare utilization, polypharmacy, hospitalizations, and mortality. Patients with multimorbidity frequently experience fragmented care, higher rates of adverse drug events, and significant psychosocial distress. The cumulative burden of disease is often underestimated by counting conditions alone; thus, biomarkers that reflect integrated pathophysiological stress are essential. The economic impact is profound, with multimorbidity driving a disproportionate share of healthcare expenditures and resource utilization in both primary and tertiary care settings.

Pathophysiology

The pathophysiology of multimorbidity is multifactorial, involving complex interactions between genetic susceptibility, environmental exposures, lifestyle factors, and chronic inflammation. Shared mechanisms such as oxidative stress, immune dysregulation, endothelial dysfunction, and neurohormonal activation link diverse chronic diseases. Biomarkers capturing these overlapping pathways include C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), fibrinogen, glycosylated hemoglobin (HbA1c), and N-terminal pro-brain natriuretic peptide (NT-proBNP). These biomarkers serve as proxies for cumulative organ system stress and help elucidate the biological basis of increased morbidity and mortality in patients with multimorbidity.

Risk Factors

Risk factors for developing multimorbidity include advancing age, low socioeconomic status, sedentary lifestyle, unhealthy diet, obesity, tobacco use, genetic predisposition, and exposure to psychosocial stressors. Socioeconomic deprivation, limited access to healthcare, and health literacy deficits further exacerbate disease burden. Chronic systemic inflammation and metabolic dysregulation, reflected in elevated inflammatory and metabolic biomarkers, are common in individuals with multiple chronic conditions. Identification of individuals at risk based on biomarker profiles may enable earlier intervention and personalized care strategies.

Clinical Features

Patients with multimorbidity present with heterogeneous clinical features, often spanning multiple organ systems. Commonly co-occurring chronic conditions include cardiovascular disease, diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease (COPD), and depression. Symptoms are frequently non-specific or overlapping, such as fatigue, dyspnea, pain, and cognitive impairment. The clinical phenotype is shaped by the interplay of pathophysiological processes, disease severity, and treatment effects. Biomarkers can aid in distinguishing disease activity, monitoring progression, and predicting complications, thereby supporting comprehensive clinical assessment.

Diagnosis

Diagnosis of cumulative healthcare burden in adults with multimorbidity requires integration of clinical history, physical examination, and objective biomarkers. Traditional indices, such as the Charlson Comorbidity Index, provide rudimentary quantification based on disease count and severity. Biomarkers enhance diagnostic accuracy by quantifying systemic inflammation (e.g., CRP, IL-6), metabolic dysfunction (e.g., HbA1c, fasting glucose), renal impairment (e.g., estimated glomerular filtration rate, cystatin C), and cardiac stress (e.g., NT-proBNP, troponins). Composite biomarker panels and multi-omics approaches hold promise for capturing the multidimensional burden of multimorbidity more precisely.

Treatment & Management

Management of multimorbidity is centered on individualized, patient-centered care that addresses the cumulative impact of multiple diseases. Biomarkers guide therapeutic decision-making by identifying patients at higher risk of adverse outcomes, informing medication selection, and monitoring treatment response. For instance, elevated CRP or NT-proBNP may prompt more aggressive cardiovascular risk reduction, while abnormal renal biomarkers may necessitate medication adjustment to prevent nephrotoxicity. Regular biomarker assessment facilitates proactive management, reduces polypharmacy-related complications, and enables timely modification of care plans.

Recent Advances / Emerging Therapies

Recent advances in biomarker science include the development of high-sensitivity assays, multi-biomarker panels, and integration with digital health technologies. Proteomic, metabolomic, and transcriptomic signatures are being explored for their ability to provide a holistic view of cumulative disease burden. Machine learning algorithms are increasingly utilized to analyze large-scale biomarker datasets, enabling risk stratification and personalized intervention. Emerging therapies targeting common inflammatory and metabolic pathways offer potential for reducing the cumulative burden, with biomarkers serving as surrogate endpoints in clinical trials. The integration of biomarker data into electronic health records supports real-time decision support and population health management.

Guideline Recommendations

Current clinical guidelines emphasize the importance of comprehensive assessment and individualized care in patients with multimorbidity. While no universal biomarker panel is recommended, guidelines advocate for regular monitoring of disease-specific and systemic biomarkers to inform risk stratification and management. The use of biomarkers is encouraged in identifying high-risk patients, guiding therapeutic choices, and evaluating treatment efficacy. Professional societies recommend interdisciplinary care models and incorporation of biomarker data into routine clinical practice to improve outcomes in this complex patient population.

Conclusion

Biomarkers play a pivotal role in assessing and managing the cumulative healthcare burden in adults with multimorbidity. They provide objective measures of pathophysiological stress, facilitate risk stratification, and guide personalized care strategies. Recent advances in biomarker discovery and application hold promise for improving patient outcomes and optimizing resource utilization. Ongoing research is warranted to validate novel biomarkers, integrate multi-omics approaches, and establish standardized protocols for their use in clinical practice. Ultimately, effective use of biomarkers will enhance the care of individuals living with multimorbidity and help address the growing challenge of cumulative healthcare burden.